Simufilam
8 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
8
Ongoing
0
Recruiting
0
Completed
5
Sites
217
Countries
5
Endpoints
140
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 140 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 38 of 140 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
6
4
4
4
4
4
4
4
2
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
8 of 8
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT05575076Open-label Extension for Phase 3 Clinical Trials of Simufilam | Simufilam Alzheimer’s disease | Age 51-89 | Ph 3 | Terminated | 134 | Jan 2025 | - | results |
| REFOCUS-ALZSimufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease | Simufilam Alzheimer’s disease | MMSE 16-27 | Ph 3 | Terminated | 89 | Dec 2024 | 1 | results |
| RETHINK-ALZSimufilam 100 mg for Mild-to-Moderate Alzheimer's Disease | Simufilam Alzheimer’s disease | MMSE 16-27 | Ph 3 | Completed | 88 | Oct 2024 | 1 | results |
| PTI-125Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients | Simufilam Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 17 | Nov 2023 | 4 | results |
| NCT05352763Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease | Simufilam Alzheimer’s disease | Age ≥50 | Ph 2 | Terminated | 11 | Dec 2024 | - | results |
| NCT04079803PTI-125 for Mild-to-moderate Alzheimer's Disease Patients | Simufilam Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 9 | Mar 2020 | 1 | results |
| NCT03748706PTI-125 for Mild-to-moderate Alzheimer's Disease Patients | Simufilam Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 2 | May 2019 | 3 | results |
| NCT03784300A Safety Study of PTI-125 in Healthy Volunteers | Simufilam Alzheimer’s disease | Age 18-45 | Ph 1 | Completed | 1 | Oct 2017 | - | results |
Showing 1-8 of 8 trials